Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405922 | 0.90 | PDE5A (0.69) | PDE5APDE6C | |
| SCHEMBL8501766 | 0.89 | PDE5A (0.62) | PDE5APDE6C | |
| SCHEMBL7524001 | 0.87 | PDE5A (0.59) | PDE5APDE6C | |
| SCHEMBL6778148 | 0.86 | PDE5A (0.69) | PDE5APDE6C | |
| SCHEMBL6358551 | 0.84 | PDE5A (0.69) | PDE5APDE6C | |
| SCHEMBL3583007 | 0.81 | PDE5A (0.80) | PDE5APDE6C | |
| SCHEMBL13500481 | 0.79 | PDE5A (0.72) | PDE5A | |
| SCHEMBL6776828 | 0.78 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL2404254 | 0.78 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL2405075 | 0.77 | PDE5A (0.63) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1285658-A2 | Treatments for female sexual dysfunction | Pfizer Productors Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885PDE6C 20/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885PDE6C 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.